drugset
drugset / Trial / NCT04608513

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

NCT04608513 ↗

Phase 1 Completed 46 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindOther

Summary

A safety and tolerability study in healthy subjects including examination of how the body takes up, distributes, and gets rid of ACT-1014-6470

Timeline

Start
2020-11-16
Primary completion
2021-09-20
Completion
2021-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ACT-1014-6470 Unknown — Oral

Indications

No indication recorded.